Blog
RSS FeedPosted by Michael Wonder on 16 Mar 2022
PHARMAC deal good news for New Zealanders
16 March 2022 - The Government is welcoming news the national drug-funding agency PHARMAC has secured an agreement for medicines ...
Posted by Michael Wonder on 16 Mar 2022
PHARMAC to fund new treatments for lung and ovarian cancer
16 March 2022 - PHARMAC has confirmed today they are funding a bundle deal which will give New Zealanders more ...
Posted by Michael Wonder on 11 Mar 2022
Diabetes NZ to kick-start campaign for PHARMAC funding for glucose monitors
11 March 2022 - Diabetes NZ wants PHARMAC to fund next-generation blood sugar monitors for people with the debilitating disease. ...
Posted by Michael Wonder on 10 Mar 2022
Ronapreve: first COVID-19 therapeutic drug to get Medsafe's approval not effective against Omicron
10 March 2022 - The first new COVID-19 therapeutic drug to get Medsafe's approval demonstrates "significantly diminished potency" against Omicron. ...
Posted by Michael Wonder on 10 Mar 2022
Thirty six medicines added to PHARMAC’s waiting list as New Zealand’s medicines crisis worsens
10 March 2022 - PHARMAC has just released its Options for Investment list, which includes 36 new medicines since it ...
Posted by Michael Wonder on 09 Mar 2022
Pūahoaho: clarity around PHARMACs priority lists
9 March 2022 - PHARMAC has released up to date information about its priority lists, including a list of ...
Posted by Michael Wonder on 07 Mar 2022
PHARMAC proposes widened access to the flu vaccine for Māori and Pacific peoples for 2022 season
8 March 2022 - PHARMAC is consulting on a proposal to widen access to the funded influenza vaccine to include Māori ...
Posted by Michael Wonder on 06 Mar 2022
The shortfalls of PHARMAC and why the public system simply can’t shoulder it alone
7 March 2022 - Rob Hennin, CEO of nib New Zealand discusses the shortfalls of the PHARMAC system when it ...
Posted by Michael Wonder on 04 Mar 2022
PHARMAC updates access criteria for remdesivir
4 March 2022 - PHARMAC has heard from our expert advisors and clinicians treating people with COVID-19 that we need to ...
Posted by Michael Wonder on 01 Mar 2022
Kiwis call on Government to increase PHARMAC funding to help fund Spinraza treatment
1 March 2022 - A group of Kiwis are calling on the Government to increase PHARMAC funding to provide better ...
Posted by Michael Wonder on 28 Feb 2022
Flu vaccine price increase
1 March 2022 - PHARMAC has confirmed that the purchase price of the annual influenza vaccine will increase by $2 ...
Posted by Michael Wonder on 28 Feb 2022
New Zealand Pharmaceutical Schedule - 1 March 2022
1 March 2022 - The March 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 28 Feb 2022
PHARMAC ensures earlier access to key COVID-19 treatment
28 February 2022 - The access criteria for remdesivir is being temporarily widened to allow hospitals to treat those with ...
Posted by Michael Wonder on 24 Feb 2022
Cystic fibrosis community disappointed with PTAC recommendations
23 February 2022 - New Zealand’s cystic fibrosis community received disappointing news today with a recommendation to PHARMAC that reduces ...
Posted by Michael Wonder on 23 Feb 2022
PHARMAC recommends funding cystic fibrosis medicine Trikafta but needs more funding
23 February 2022 - PHARMAC’s clinical experts are recommending cystic fibrosis drug Trikafta be funded for those aged over 12 ...